(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burd	en						
hours per response	0.5						
	OMB Number: Estimated average burd						

5. Relationship of Reporting Person(s) to Issuer

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * VANCE DOLLY					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC.,, 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 03/30/2009							X	X Officer (give title below) Other (specify below) SVP, Gen. Counsel, Corp. Sec.				
(Street)				4. If a	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
SOUTH (Ci		NCISCO, CA 94 (State)	(Zip)														
(CI	(y)	(State)	(Zip)							vative	e Securities	Acquired	Disposed of	f, or Benefic	ially Owned		
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Ye		ecuti y		3. Transaction Code (Instr. 8)		(A	4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)		(D) Owned Following Transaction(s)		eurities Beneficially g Reported		wnership of B	Beneficial
				(M	Ionth	/Day/Year)					(A) or	Ì	0		or (I		
							(Code	V At	noun	t (D)	Price			(I	nstr. 4)	
			Table					tl c	nis form urrently , Dispos	n are / vali ed of		red to res ontrol num cially Own	pond unles iber.		contained ir displays a	SEC 14	74 (9-02)
1. Title of Derivative Conversion or Exercise (Instr. 3) Price of Derivative Security	Exercise (Month/Day/Year) any (Month/Day/rivative		Code	5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect					
				Code	V	(A)	(D)	Date Exercis	sable	Ex Da	piration	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (Right to Buy)	\$ 6.49	03/30/2009		A		100,000		04/30	/2009	03	3/30/2019	Commo	n 100,000	\$ 0	100,000	D	

Reporting Owners

		Relationships						
Report	ing Owner Name / Address	Director	10% Owner	Officer	Other			
1180 VETE	OLLY ARMACEUTICALS, INC., ERANS BLVD. IN FRANCISCO, CA 94080			SVP, Gen. Counsel, Corp. Sec.				

Signatures

/s/Dolly Vance	03/31/2009
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest monthly over one (1) year from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.